8-K: Sensei Bio Presents Promising Early Data for Conditionally Active Antibody SNS-101 in Cancer Trials

Sensei Biotherapeutics' lead drug candidate, SNS-101, shows encouraging initial clinical activity and a favorable safety profile in early-stage trials, targeting the VISTA immune checkpoint.

Summary

• Sensei Biotherapeutics is developing conditionally active antibodies that target the tumor microenvironment to improve cancer treatment.
• Their lead candidate, SNS-101, targets VISTA, a key immune checkpoint, and is currently in a Phase 1/2 clinical trial.
• SNS-101 has shown a well-tolerated safety profile, potentially best-in-class pharmacokinetics, and initial signs of clinical activity.
• The company's technology platform is designed to overcome the limitations of traditional antibodies by selectively binding to targets in the low-pH tumor microenvironment.
• The company has a cash runway into the fourth quarter of 2025, which is expected to fund operations midway into Phase 2 studies of SNS-101.
• Initial Phase 1 expansion data is expected by year-end 2024.
• The company has entered into a clinical supply agreement with Regeneron to evaluate SNS-101 in combination with Libtayo, and a research agreement with the National Cancer Institute to further study VISTA.
• The company has also entered into a research collaboration with Robert Schreiber, Ph.D. to further study the mechanism of SNS-101's anti-tumor activity.
• The company's technology is based on pH-sensitive antibodies that selectively bind to targets in the low-pH tumor microenvironment, which is around pH 6.0, compared to the normal physiological pH of 7.4.
• The company is also developing other drug candidates, including SNS-102 targeting VSIG-4, SNS-103 targeting ENTPDase1/CD39, and SNS-201 targeting VISTA and CD28.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising early clinical data, a strong cash position, and strategic partnerships. The company's technology is innovative and addresses a significant unmet need in cancer treatment. However, there are inherent risks in drug development, and some adverse events were reported.

Positives

• SNS-101 has shown a well-tolerated safety profile, with no dose-limiting toxicities observed.
• The drug has demonstrated linear elimination kinetics and a long half-life, supporting less frequent dosing.
• Initial clinical data suggests anti-tumor activity in patients with tumors typically unresponsive to PD-1 monotherapy.
• The company's TMAb platform has the potential to unlock previously undruggable immune targets.
• The company has a strong cash position to fund operations into late 2025.
• The company has key partnerships with Regeneron and the National Cancer Institute.

Negatives

• One patient death occurred during the trial, though it was related to disease progression and not the study drug.
• Some patients experienced adverse events, including cytokine release syndrome and elevated liver enzymes, though most were low grade.
• Some patients discontinued treatment due to adverse events or disease progression.
• The majority of patients enrolled in the study had tumors typically unresponsive to PD-1/PD-L1 therapy, which may make it difficult to assess the drug's efficacy in responsive tumors.

Risks

• The development of therapeutic product candidates involves inherent uncertainties, including preclinical discovery and development.
• There is a risk of delay or cessation of any clinical trials of Sensei's product candidates.
• Prior results may not be replicated in ongoing or future studies.
• The company relies on third parties over which it may not always have full control.
• There are risks regarding the accuracy of the company's estimates of expenses, capital requirements, and needs for additional financing.
• The company's actual future results may be materially different from what they expect.

Future Outlook

The company expects to release initial data from the Phase 1 dose expansion study by the end of 2024 and anticipates that its current cash reserves will fund operations midway into Phase 2 clinical studies for SNS-101.

Management Comments

• Sensei's proprietary platform is designed to harness conditional activation of antibodies to widen the therapeutic window and enable druggability of promising oncology targets.
• SNS-101 has demonstrated the ability to overcome hurdles associated with drugging VISTA, including a well-tolerated safety profile, potentially best-in-class PK, and initial signs of promising clinical activity.

Industry Context

The document highlights the challenges in the immuno-oncology field, particularly with traditional checkpoint inhibitors, and positions Sensei's technology as a solution to these issues. The company is targeting VISTA, a checkpoint that has been difficult to drug due to toxicity issues, and is using a pH-sensitive approach to improve safety and efficacy. The document also notes the large and growing market for immuno-oncology drugs, with a significant portion of patients not responding to current treatments.

Comparison to Industry Standards

• The document compares SNS-101 to other VISTA-targeting antibodies, such as JNJ-61610588, which was halted due to severe toxicities.
• SNS-101 is differentiated by its pH-sensitive binding, which is designed to reduce off-target effects and improve pharmacokinetics.
• The document also references Soliris and Ultomiris, which are examples of pH-sensitive antibodies that have achieved commercial success.
• The document highlights that other VISTA programs have shown issues with PK sink, which SNS-101 is designed to overcome.
• The document shows that SNS-101 has a favorable single-dose PK profile in preclinical studies with no significant TMDD in human VISTA knock-in mice or non-human primates.

Stakeholder Impact

• Shareholders may benefit from the positive clinical data and the company's strong cash position.
• Employees may be impacted by the company's progress and future growth.
• Patients may benefit from the development of new and effective cancer treatments.
• Partners such as Regeneron and the National Cancer Institute may benefit from the collaboration and research.

Next Steps

• Patient enrollment is advancing in dose expansion cohorts.
• The company is exploring two dose levels in the combination cohort to further optimize study design for Phase 2.
• Expansion tumor types are focused on a basket of hot tumors and one cold tumor.
• Additional tumor types and doses may be considered.
• Initial data from dose expansion is expected in Q4 2024.
• The company plans to have an end of Phase 1 FDA meeting.

Key Dates

Keywords

Immuno-oncology, VISTA, Conditionally Active Antibodies, Tumor Microenvironment, SNS-101, Checkpoint Inhibitors, Cancer Therapy, Clinical Trials, pH-sensitive Antibodies, T-cell Activation